523 related articles for article (PubMed ID: 36737746)
21. Shorter-acting glucagon-like peptide-1 receptor agonists are associated with increased development of gastro-oesophageal reflux disease and its complications in patients with type 2 diabetes mellitus: a population-level retrospective matched cohort study.
Liu BD; Udemba SC; Liang K; Tarabichi Y; Hill H; Fass R; Song G
Gut; 2024 Jan; 73(2):246-254. PubMed ID: 37739778
[TBL] [Abstract][Full Text] [Related]
22. Glucagon like peptide-1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: Population-based cohort study.
Pradhan R; Yu OHY; Platt RW; Azoulay L
Diabet Med; 2024 Apr; 41(4):e15248. PubMed ID: 37876318
[TBL] [Abstract][Full Text] [Related]
23. Causal Relationship between Adiponectin and Diabetic Retinopathy: A Mendelian Randomization Study in an Asian Population.
Huang YC; Chang YW; Cheng CW; Wu CM; Liao WL; Tsai FJ
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33374471
[TBL] [Abstract][Full Text] [Related]
24. Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies.
Li L; Li S; Liu J; Deng K; Busse JW; Vandvik PO; Wong E; Sohani ZN; Bala MM; Rios LP; Malaga G; Ebrahim S; Shen J; Zhang L; Zhao P; Chen Q; Wang Y; Guyatt GH; Sun X
BMC Cardiovasc Disord; 2016 May; 16():91. PubMed ID: 27169565
[TBL] [Abstract][Full Text] [Related]
25. Glucagon-like peptide-1 (GLP-1) receptor agonists in type 2 diabetes and long-term complications: FOCUS on retinopathy.
Marchand L; Luyton C; Bernard A
Diabet Med; 2021 Jan; 38(1):e14390. PubMed ID: 32799379
[No Abstract] [Full Text] [Related]
26. Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Cheng L; Hu Y; Li YY; Cao X; Bai N; Lu TT; Li GQ; Li N; Wang AN; Mao XM
Diabetes Metab Res Rev; 2019 Oct; 35(7):e3168. PubMed ID: 30974033
[TBL] [Abstract][Full Text] [Related]
27. Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials.
Zhang YS; Weng WY; Xie BC; Meng Y; Hao YH; Liang YM; Zhou ZK
Osteoporos Int; 2018 Dec; 29(12):2639-2644. PubMed ID: 30083774
[TBL] [Abstract][Full Text] [Related]
28. Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study.
Patorno E; Everett BM; Goldfine AB; Glynn RJ; Liu J; Gopalakrishnan C; Kim SC
Diabetes Obes Metab; 2016 Aug; 18(8):755-65. PubMed ID: 27003762
[TBL] [Abstract][Full Text] [Related]
29. The effect of hypothyroidism on the risk of diabetes and its microvascular complications: a Mendelian randomization study.
Fang T; Deng X; Wang J; Han F; Liu X; Liu Y; Sun B; Chen L
Front Endocrinol (Lausanne); 2023; 14():1288284. PubMed ID: 38116309
[TBL] [Abstract][Full Text] [Related]
30. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective.
Jensterle M; Janez A; Fliers E; DeVries JH; Vrtacnik-Bokal E; Siegelaar SE
Hum Reprod Update; 2019 Jul; 25(4):504-517. PubMed ID: 31260047
[TBL] [Abstract][Full Text] [Related]
31. Assessment of the association between genetic factors regulating thyroid function and microvascular complications in diabetes: A two-sample Mendelian randomization study in the European population.
Li H; Li M; Dong S; Zhang S; Dong A; Zhang M
Front Endocrinol (Lausanne); 2023; 14():1126339. PubMed ID: 36926020
[TBL] [Abstract][Full Text] [Related]
32. Comparing the use of individual and composite terms to evaluate adverse drug event disproportionality: a focus on glucagon-like peptide-1 receptor agonists and diabetic retinopathy.
Dauner DG; Farley JF
Expert Opin Drug Saf; 2021 Apr; 20(4):475-480. PubMed ID: 33554677
[No Abstract] [Full Text] [Related]
33. Possible Advantage of Glucagon-Like Peptide 1 Receptor Agonists for Kidney Transplant Recipients With Type 2 Diabetes.
Sato T; Azuma Y; Ozone C; Okazaki M; Takeda A; Okada M; Futamura K; Hiramitsu T; Goto N; Narumi S; Watarai Y
J Clin Endocrinol Metab; 2023 Sep; 108(10):2597-2603. PubMed ID: 36974363
[TBL] [Abstract][Full Text] [Related]
34. Association between Glucose-lowering Treatments and Risk of Diabetic Retinopathy in People with Type 2 Diabetes: A Nationwide Cohort Study.
Hasselstrøm Jensen J; Vestergaard P; Hasselstrøm Jensen M
Curr Drug Saf; 2024; 19(2):236-243. PubMed ID: 37078347
[TBL] [Abstract][Full Text] [Related]
35. Diabetic retinopathy risk in patients with unhealthy lifestyle: A Mendelian randomization study.
Su Z; Wu Z; Liang X; Xie M; Xie J; Li H; Wang X; Jiang F
Front Endocrinol (Lausanne); 2022; 13():1087965. PubMed ID: 36733810
[TBL] [Abstract][Full Text] [Related]
36. Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials.
Dawed AY; Mari A; Brown A; McDonald TJ; Li L; Wang S; Hong MG; Sharma S; Robertson NR; Mahajan A; Wang X; Walker M; Gough S; Hart LM'; Zhou K; Forgie I; Ruetten H; Pavo I; Bhatnagar P; Jones AG; Pearson ER;
Lancet Diabetes Endocrinol; 2023 Jan; 11(1):33-41. PubMed ID: 36528349
[TBL] [Abstract][Full Text] [Related]
37. Relationship between circulating metabolites and diabetic retinopathy: a two-sample Mendelian randomization analysis.
Ma L; Dong Y; Li Z; Meng J; Zhao B; Wang Q
Sci Rep; 2024 Feb; 14(1):4964. PubMed ID: 38424453
[TBL] [Abstract][Full Text] [Related]
38. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
Dong YH; Chang CH; Lin JW; Yang WS; Wu LC; Toh S
Diabetes Obes Metab; 2022 Aug; 24(8):1623-1637. PubMed ID: 35491533
[TBL] [Abstract][Full Text] [Related]
39. Diabetic Retinopathy and Brain Structure, Cognition Function, and Dementia: A Bidirectional Mendelian Randomization Study.
Chai YH; Han YP; Zhang JY; Zhou JB
J Alzheimers Dis; 2024; 97(3):1211-1221. PubMed ID: 38217603
[TBL] [Abstract][Full Text] [Related]
40. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
